In a report released on February 28, David Martin PhD from Bloom Burton maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report), with a price target of $10.00.
David Martin PhD has given his Buy rating due to a combination of factors including Aurinia Pharmaceuticals’ strong financial performance and strategic positioning. The company reported a significant increase in Lupkynis product revenue, which grew by 36% year-over-year and 4% quarter-over-quarter, aligning closely with expectations.
Furthermore, despite a conservative revenue guidance for 2025, which might be influenced by a reduced sales force, the company’s focus on key projects like AUR200 and Voclo ANDA suggests potential for future growth. These elements, combined with effective expense management, underpin the positive outlook and justify the Buy rating.
In another report released on February 27, TD Cowen also maintained a Buy rating on the stock with a $11.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AUPH in relation to earlier this year.